Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study. avacta.com/avacta-announc… #AVCT
Avacta
1,845 posts
Avacta
@avacta
Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
- AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing. hubs.ly/Q0115fc40 #AVCT
- Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update. avacta.com/successful-com… #AVCT
- Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study. avacta.com/successful-com… #AVCT
- Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin. hubs.ly/Q013qRjy0 #AVCT
- Avacta is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISION programme, AVA6000, a tumour activated form of doxorubicin. avacta.com/als-6000-101-p… #AVCT
- Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000. hubs.ly/H0_Wkjz0 #AVCT
- We will be in Boston next week to present positive new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. avacta.com/avacta-to-pres… See you all there! #AVCT #cancerresearch #innovation #oncology
- On #WorldCancerDay we are proud to be a part of the global effort to improve patient’s lives through more advanced cancer treatments. Find out about the exciting work taking place at Avacta with our pre|CISION™ and Affimer® platforms: avacta.com/therapeutics/
- Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin. hubs.ly/Q01fR1fL0 #AVCT
- AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration. hubs.ly/Q01ly1Tn0 #AVCT
- The poster being presented today at AACR, ‘AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a) mediated cleavage’, is now available to download at: avacta.com/about/resource… #AVCT